Vancouver –News Direct– Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.

Moreau told Proactive the safety review committee has approved moving the study forward with an escalated dose after observing no safety or tolerability issues. This study will include up to 60 healthy volunteers, including both psychedelic experienced and psychedelic naïve subjects.


  Subscribe to news from
Algernon Pharmaceuticals

Be the first to know when breaking news are released.



Contact Details

Proactive Canada

+1 604-688-8158

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-subsidiary-completes-first-dosing-in-phase-1-clinical-study-of-dmt-635930354